Watch Ticker

Cassava Sciences, Inc.

Go to Cassava Sciences, Inc. Website

$2.29

0.00 (0.00%)

Live

Previous Close

$2.29

Day Range

$0 - $0

Previous Day Range

$2.15 - $2.39

Market Cap

$102.4 million USD

Day Vol.

Previous Day Vol.

1.6 million

Currency

USD

Primary Exchange

Nasdaq

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for ...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Delveinsight - LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight

LEQEMBI, an Alzheimer's disease treatment developed by Biogen and Eisai, has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. The Alzheimer's disease market is highly competitive, with numerous companies advancing therapies in the pipeline.

Related tickers: BIIB, ANVS, SAVA, NVO, LLY, ESAIY.

Read Full Article

N/A - SAVA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit

A securities class action lawsuit has been filed against Cassava Sciences, Inc. (SAVA) on behalf of investors who purchased or acquired Cassava securities between February 7, 2024, and November 24, 2024. The lawsuit alleges that Cassava misrepresented the ability of its drug, simufilam, to abate the progression of Alzheimer's Disease.

Related tickers: SAVA.

Read Full Article

Trending Tickers

Please sign in to view